Not available
Quote | Nektar Therapeutics (NASDAQ:NKTR)
Last: | $1.29 |
---|---|
Change Percent: | -0.77% |
Open: | $1.31 |
Close: | $1.29 |
High: | $1.335 |
Low: | $1.18 |
Volume: | 2,299,917 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Nektar Therapeutics (NASDAQ:NKTR)
2024-06-20 23:47:38 ET Summary Nektar Therapeutics has two Phase IIb studies underway for rezpeg in atopic dermatitis and severe alopecia areata, with read-outs expected in 1H'25. Success in either indication would significantly boost Nektar's prospects (and share price), but Phas...
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 PR Newswire – NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic ...
Message Board Posts | Nektar Therapeutics (NASDAQ:NKTR)
Subject | By | Source | When |
---|---|---|---|
pincher chart on the daily and weekly, I | DavidTrader | investorshub | 03/27/2023 5:14:28 PM |
Hmmm just crickets around here, I dont mind | Lilman72003 | investorshub | 03/22/2023 8:17:33 PM |
whytestocks: $NKTR News Article - Nektar Therapeutics' President and CEO, Howard Robin, To Present a | whytestocks | investorshangout | 01/04/2023 5:25:56 PM |
whytestocks: $NKTR News Article - Nektar Therapeutics to Host Webcast Conference Call for Analysts & | whytestocks | investorshangout | 04/22/2022 6:55:51 PM |
NKTR -24%/AH on_termination_of Bempeg program following phase-3 failures | DewDiligence | investorshub | 04/14/2022 9:23:32 PM |
News, Short Squeeze, Breakout and More Instantly...
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 PR Newswire – NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic ...
Nektar Management to Present at Upcoming Investor Conferences PR Newswire SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare C...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...